Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received a 3-day suspension order for the drug license of a single store (Ritecure Raghuram Children Hospital) located in Nellore district, Andhra Pradesh. The order was issued by the Assistant Director of the District Sales Licensing Authority, Drug Control Administration, under Rule 65 of the Drugs and Cosmetics Act, 1940, and was received on May 9, 2025. The company has disclosed a potential revenue loss of approximately Rs 1.80 lakhs from this suspension. The filing was made under SEBI Listing Regulations to keep investors informed of the regulatory action.
The financial impact is negligible at around Rs 1.80 lakhs for a single store, so it is unlikely to materially affect the company's overall operations or stock price. However, repeated or wider regulatory actions against drug licenses could raise concerns about compliance practices across the retail pharmacy chain.